Do analysts recommend ABOS or BYSI?

Acumen Pharmaceuticals presently has a consensus price target of $8.00, indicating a potential upside of 224.54%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Acumen Pharmaceuticals is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acumen Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ABOS or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -123.07% -79.41% BeyondSpring N/A N/A -14.00%

Does the media prefer ABOS or BYSI?

In the previous week, Acumen Pharmaceuticals had 1 more articles in the media than BeyondSpring. MarketBeat recorded 2 mentions for Acumen Pharmaceuticals and 1 mentions for BeyondSpring. Acumen Pharmaceuticals' average media sentiment score of 0.00 equaled BeyondSpring'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BeyondSpring 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BYSI or NKTX?

Nkarta has a consensus price target of $11.40, suggesting a potential upside of 386.14%. Given Nkarta's stronger consensus rating and higher probable upside, analysts plainly believe Nkarta is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nkarta 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Is BYSI or NKTX more profitable?

BeyondSpring's return on equity of 0.00% beat Nkarta's return on equity. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -14.00% Nkarta N/A -30.90% -24.20%

Does the media prefer BYSI or NKTX?

In the previous week, Nkarta had 7 more articles in the media than BeyondSpring. MarketBeat recorded 8 mentions for Nkarta and 1 mentions for BeyondSpring. Nkarta's average media sentiment score of 0.11 beat BeyondSpring's score of 0.00 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeyondSpring 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nkarta 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate TNYA or BYSI?

Tenaya Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 426.32%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tenaya Therapeutics is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenaya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TNYA or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Tenaya Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tenaya Therapeutics N/A -83.75% -66.53% BeyondSpring N/A N/A -14.00%

Does the media refer more to TNYA or BYSI?

In the previous week, Tenaya Therapeutics had 17 more articles in the media than BeyondSpring. MarketBeat recorded 18 mentions for Tenaya Therapeutics and 1 mentions for BeyondSpring. Tenaya Therapeutics' average media sentiment score of 0.53 beat BeyondSpring's score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeyondSpring 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate HUMA or BYSI?

Humacyte presently has a consensus price target of $6.25, indicating a potential upside of 771.69%. Given Humacyte's stronger consensus rating and higher probable upside, analysts plainly believe Humacyte is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Humacyte 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HUMA or BYSI more profitable?

BeyondSpring has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. BeyondSpring's return on equity of 0.00% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Humacyte -4,836.06% -2,914.18% -89.45% BeyondSpring N/A N/A -14.00%

Does the media refer more to HUMA or BYSI?

In the previous week, Humacyte had 4 more articles in the media than BeyondSpring. MarketBeat recorded 5 mentions for Humacyte and 1 mentions for BeyondSpring. Humacyte's average media sentiment score of 0.50 beat BeyondSpring's score of 0.00 indicating that Humacyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BeyondSpring 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CRBU or BYSI?

In the previous week, Caribou Biosciences had 2 more articles in the media than BeyondSpring. MarketBeat recorded 3 mentions for Caribou Biosciences and 1 mentions for BeyondSpring. Caribou Biosciences' average media sentiment score of 0.51 beat BeyondSpring's score of 0.00 indicating that Caribou Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caribou Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeyondSpring 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

BeyondSpring (BYSI) Competitors

$0.79 +0.00 (+0.55%)

As of 01:55 PM Eastern

Compare

BYSI vs. ABOS, NKTX, TNYA, HUMA, and CRBU

Should you buy BeyondSpring stock or one of its competitors? BeyondSpring's main competitors and comparable companies include Acumen Pharmaceuticals (ABOS), Nkarta (NKTX), Tenaya Therapeutics (TNYA), Humacyte (HUMA), and Caribou Biosciences (CRBU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BeyondSpring compare to Acumen Pharmaceuticals?

Acumen Pharmaceuticals (NASDAQ:ABOS) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Acumen Pharmaceuticals has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market.

In the previous week, Acumen Pharmaceuticals had 1 more articles in the media than BeyondSpring. MarketBeat recorded 2 mentions for Acumen Pharmaceuticals and 1 mentions for BeyondSpring. Acumen Pharmaceuticals' average media sentiment score of 0.00 equaled BeyondSpring'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeyondSpring	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeyondSpring's return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
BeyondSpring	N/A	N/A	-14.00%

BeyondSpring has higher revenue and earnings than Acumen Pharmaceuticals. BeyondSpring is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A
BeyondSpring	$1.75M	18.56	-$1.01M	-$0.14	N/A

Acumen Pharmaceuticals presently has a consensus price target of $8.00, indicating a potential upside of 224.54%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Acumen Pharmaceuticals is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 10.2% of Acumen Pharmaceuticals shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

BeyondSpring beats Acumen Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does BeyondSpring compare to Nkarta?

BeyondSpring (NASDAQ:BYSI) and Nkarta (NASDAQ:NKTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

In the previous week, Nkarta had 7 more articles in the media than BeyondSpring. MarketBeat recorded 8 mentions for Nkarta and 1 mentions for BeyondSpring. Nkarta's average media sentiment score of 0.11 beat BeyondSpring's score of 0.00 indicating that Nkarta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeyondSpring	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nkarta	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 29.3% of BeyondSpring shares are held by insiders. Comparatively, 9.8% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BeyondSpring's return on equity of 0.00% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
Nkarta	N/A	-30.90%	-24.20%

BeyondSpring has higher revenue and earnings than Nkarta. BeyondSpring is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	18.56	-$1.01M	-$0.14	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

Nkarta has a consensus price target of $11.40, suggesting a potential upside of 386.14%. Given Nkarta's stronger consensus rating and higher probable upside, analysts plainly believe Nkarta is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

BeyondSpring has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market. Comparatively, Nkarta has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

Summary

Nkarta beats BeyondSpring on 9 of the 15 factors compared between the two stocks.

How does BeyondSpring compare to Tenaya Therapeutics?

Tenaya Therapeutics (NASDAQ:TNYA) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Tenaya Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 426.32%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tenaya Therapeutics is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Tenaya Therapeutics had 17 more articles in the media than BeyondSpring. MarketBeat recorded 18 mentions for Tenaya Therapeutics and 1 mentions for BeyondSpring. Tenaya Therapeutics' average media sentiment score of 0.53 beat BeyondSpring's score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeyondSpring	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeyondSpring has higher revenue and earnings than Tenaya Therapeutics. BeyondSpring is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A
BeyondSpring	$1.75M	18.56	-$1.01M	-$0.14	N/A

BeyondSpring's return on equity of 0.00% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-83.75%	-66.53%
BeyondSpring	N/A	N/A	-14.00%

Tenaya Therapeutics has a beta of 2.83, indicating that its share price is 183% more volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market.

90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 2.5% of Tenaya Therapeutics shares are held by company insiders. Comparatively, 29.3% of BeyondSpring shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Tenaya Therapeutics beats BeyondSpring on 9 of the 15 factors compared between the two stocks.

How does BeyondSpring compare to Humacyte?

Humacyte (NASDAQ:HUMA) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

44.7% of Humacyte shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 3.1% of Humacyte shares are owned by company insiders. Comparatively, 29.3% of BeyondSpring shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BeyondSpring has lower revenue, but higher earnings than Humacyte. BeyondSpring is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	78.03	-$40.83M	-$0.57	N/A
BeyondSpring	$1.75M	18.56	-$1.01M	-$0.14	N/A

Humacyte presently has a consensus price target of $6.25, indicating a potential upside of 771.69%. Given Humacyte's stronger consensus rating and higher probable upside, analysts plainly believe Humacyte is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Humacyte had 4 more articles in the media than BeyondSpring. MarketBeat recorded 5 mentions for Humacyte and 1 mentions for BeyondSpring. Humacyte's average media sentiment score of 0.50 beat BeyondSpring's score of 0.00 indicating that Humacyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Humacyte	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeyondSpring	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Humacyte has a beta of 2.54, suggesting that its stock price is 154% more volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market.

BeyondSpring has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. BeyondSpring's return on equity of 0.00% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,836.06%	-2,914.18%	-89.45%
BeyondSpring	N/A	N/A	-14.00%

Summary

Humacyte beats BeyondSpring on 10 of the 16 factors compared between the two stocks.

How does BeyondSpring compare to Caribou Biosciences?

Caribou Biosciences (NASDAQ:CRBU) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

BeyondSpring has lower revenue, but higher earnings than Caribou Biosciences. BeyondSpring is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16M	15.06	-$148.12M	-$1.42	N/A
BeyondSpring	$1.75M	18.56	-$1.01M	-$0.14	N/A

In the previous week, Caribou Biosciences had 2 more articles in the media than BeyondSpring. MarketBeat recorded 3 mentions for Caribou Biosciences and 1 mentions for BeyondSpring. Caribou Biosciences' average media sentiment score of 0.51 beat BeyondSpring's score of 0.00 indicating that Caribou Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caribou Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeyondSpring	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 8.5% of Caribou Biosciences shares are owned by insiders. Comparatively, 29.3% of BeyondSpring shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Caribou Biosciences presently has a consensus target price of $8.67, indicating a potential upside of 411.31%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Caribou Biosciences is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Caribou Biosciences has a beta of 2.38, suggesting that its share price is 138% more volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market.

BeyondSpring has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,189.14%. BeyondSpring's return on equity of 0.00% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%
BeyondSpring	N/A	N/A	-14.00%

Summary

Caribou Biosciences beats BeyondSpring on 10 of the 17 factors compared between the two stocks.

Get BeyondSpring News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BYSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BYSI vs. The Competition

Export

Metric	BeyondSpring	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$32.49M	$3.71B	$7.01B	$12.84B
Dividend Yield	N/A	3.77%	2.58%	10.06%
P/E Ratio	-5.64	9.17	268.68	24.76
Price / Sales	18.56	1,249.44	583.24	95.98
Price / Cash	7.66	44.95	28.89	37.42
Price / Book	-1.34	17.97	11.34	6.43
Net Income	-$1.01M	-$13.23M	$3.44B	$347.05M
7 Day Performance	-20.20%	3.72%	2.28%	0.90%
1 Month Performance	-45.14%	-1.14%	-0.17%	-0.69%
1 Year Performance	-61.46%	62.09%	76.26%	22.15%

BeyondSpring Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BYSI BeyondSpring	0.0402 of 5 stars	$0.79 +0.5%	N/A	-60.7%	$32.49M	$1.75M	N/A	80	News Coverage Upcoming Earnings
ABOS Acumen Pharmaceuticals	1.7846 of 5 stars	$2.24 flat	$8.00 +257.1%	+78.7%	$161.79M	N/A	N/A	20
NKTX Nkarta	4.4467 of 5 stars	$2.20 -2.7%	$10.75 +388.6%	+24.2%	$161.69M	N/A	N/A	140	News Coverage Earnings Report Analyst Forecast Gap Down
TNYA Tenaya Therapeutics	3.0389 of 5 stars	$0.78 +5.8%	$4.00 +409.7%	+10.2%	$160.93M	N/A	N/A	110	News Coverage Earnings Report Upcoming Earnings Analyst Revision
HUMA Humacyte	3.4315 of 5 stars	$0.73 +2.3%	$6.25 +757.6%	-70.0%	$158.12M	$2.04M	N/A	150	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BYSI) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BeyondSpring (BYSI) Competitors

BYSI vs. ABOS, NKTX, TNYA, HUMA, and CRBU

How does BeyondSpring compare to Acumen Pharmaceuticals?

Summary

How does BeyondSpring compare to Nkarta?

Summary

How does BeyondSpring compare to Tenaya Therapeutics?

Summary

How does BeyondSpring compare to Humacyte?

Summary

How does BeyondSpring compare to Caribou Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI vs. The Competition

BeyondSpring Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BeyondSpring (BYSI) Competitors

BYSI vs. ABOS, NKTX, TNYA, HUMA, and CRBU

How does BeyondSpring compare to Acumen Pharmaceuticals?

Which has more risk & volatility, ABOS or BYSI?

Does the media prefer ABOS or BYSI?

Is ABOS or BYSI more profitable?

Which has stronger earnings & valuation, ABOS or BYSI?

Do analysts recommend ABOS or BYSI?

Do institutionals & insiders have more ownership in ABOS or BYSI?

Summary

How does BeyondSpring compare to Nkarta?

Does the media prefer BYSI or NKTX?

Do institutionals and insiders hold more shares of BYSI or NKTX?

Is BYSI or NKTX more profitable?

Which has higher valuation & earnings, BYSI or NKTX?

Do analysts prefer BYSI or NKTX?

Which has more risk and volatility, BYSI or NKTX?

Summary

How does BeyondSpring compare to Tenaya Therapeutics?

Do analysts rate TNYA or BYSI?

Does the media refer more to TNYA or BYSI?

Which has preferable earnings & valuation, TNYA or BYSI?

Is TNYA or BYSI more profitable?

Which has more volatility & risk, TNYA or BYSI?

Do insiders & institutionals have more ownership in TNYA or BYSI?

Summary

How does BeyondSpring compare to Humacyte?

Do insiders & institutionals believe in HUMA or BYSI?

Which has better earnings and valuation, HUMA or BYSI?

Do analysts rate HUMA or BYSI?

Does the media refer more to HUMA or BYSI?

Which has more volatility & risk, HUMA or BYSI?

Is HUMA or BYSI more profitable?

Summary

How does BeyondSpring compare to Caribou Biosciences?

Which has better earnings & valuation, CRBU or BYSI?

Does the media favor CRBU or BYSI?

Do institutionals & insiders have more ownership in CRBU or BYSI?

Do analysts prefer CRBU or BYSI?

Which has more risk & volatility, CRBU or BYSI?

Is CRBU or BYSI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI vs. The Competition

BeyondSpring Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools